Charles Schwab’s Genocea Biosciences, Inc. GNCA Stock Holding History

Charles Schwab’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-21,025	Closed	-$177K	–	3184
2018 Q1	$177K	Buy	+21,025	New	+$175K	﹤0.01%	3009
2017 Q4	–	Sell	-6,138	Closed	-$72K	–	3069
2017 Q3	$72K	Hold	6,138	–	–	﹤0.01%	3064
2017 Q2	$257K	Buy	+6,138	New	+$296K	﹤0.01%	2929
2016 Q2	–	Sell	-3,328	Closed	-$207K	–	3165
2016 Q1	$207K	Hold	3,328	–	–	﹤0.01%	2893
2015 Q4	$141K	Hold	3,328	–	–	﹤0.01%	3018
2015 Q3	$183K	Hold	3,328	–	–	﹤0.01%	2972
2015 Q2	$366K	Buy	+3,328	New	+$309K	﹤0.01%	2794

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab's GNCA Position: Q2 2018 in Review

Charles Schwab sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2018, closing a stake of 21,025 shares — an estimated $177K sold.

Charles Schwab first reported a position in GNCA in Q2 2015 and held it in 7 quarters. The position peaked at $366K in Q2 2015. 54 funds tracked by Wall St. Rank hold GNCA as of Q2 2018.

Charles Schwab reported no remaining Genocea Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
Charles Schwab sold 21,025 Genocea Biosciences, Inc. shares in Q2 2018, an estimated $177K.
Charles Schwab first reported a position in Genocea Biosciences, Inc. in Q2 2015 and held it in 7 quarters.
Charles Schwab's Genocea Biosciences, Inc. position peaked at $366K in Q2 2015.
54 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2018.

Based on Charles Schwab's 13F filing for Q2 2018, filed 8 Aug 2018.